Palmitoylethanolamide (PEA) Encyclopedia — Scientific Background

What Is Palmitoylethanolamide?

Palmitoylethanolamide (PEA, CAS 544-31-0), also known as palmidrol or N-(2-hydroxyethyl)hexadecanamide, is an endogenous fatty acid amide belonging to the N-acylethanolamine family. It is chemically characterized by the molecular formula C₁₈H₃₇NO₂ and a molecular weight of 299.5 g/mol. PEA is a natural fatty acid amide that is both a food component and an endogenously synthesized compound, with potential analgesic and anti-inflammatory activities. Upon administration, palmidrol may inhibit the release of pro-inflammatory mediators from activated mast cells, thereby reducing inflammation and pain.

The Endocannabinoid System and PEA

PEA is a member of the fatty-acid ethanolamide family and acts peripherally as an endogenous PPAR-α ligand, exerting analgesic and anti-inflammatory effects. PEA is an endogenous endocannabinoid receptor agonist, a simple fatty acid amide, and originally a food component, commonly isolated from soybeans, peanuts, and egg yolks. PEA is produced by the body in response to inflammation and pain and plays a crucial role in regulating cellular signaling pathways, making it an essential component of the body‘s natural defense mechanisms.

Mechanisms of Action

PPAR-α Activation — The Primary Molecular Target

The nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) is the molecular target responsible for the anti-inflammatory properties of PEA. PEA selectively activates PPAR-α in vitro with an EC50 value of 3.1 ± 0.4 μM and induces the expression of PPAR-α mRNA when applied topically to mouse skin. In two animal models, carrageenan-induced paw edema and phorbol ester-induced ear edema, PEA attenuates inflammation in wild-type mice but has no effect in mice deficient in PPAR-α. PEA prevents IκB-α degradation and NF-κB nuclear translocation, thereby reducing the production of pro-inflammatory mediators.

Mast Cell Modulation

Upon administration, palmidrol may inhibit the release of pro-inflammatory mediators from activated mast cells. This may reduce inflammation and pain. The “ALIA” mechanism (Autacoid Local Inflammation Antagonism) describes PEA’s ability to downregulate mast cell activation and reduce the release of histamine, serotonin, and other inflammatory mediators.

Neuroprotective Effects via PPAR-α

PEA is able to blunt Aβ-induced astrocyte activation and, subsequently, to improve neuronal survival through selective PPARα activation. The results indicate that PEA exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. Through activation of PPARα, PEA may stimulate neurosteroid synthesis, thereby modulating several biological functions mediated by GABA(A) receptors.

Anti-Inflammatory and Analgesic Pathways

PEA prevents IκB-α degradation and NF-κB nuclear translocation, reducing the production of pro-inflammatory mediators. PEA has demonstrated antinociceptive effects in several animal models and inhibits peripheral inflammation in rodents via a PPAR-α-mediated mechanism, directly intervening in the nervous tissue alterations responsible for pain.

Clinical Evidence

Acute Menstrual Pain — Randomized Controlled Trial

A randomized, double-blind, placebo-controlled crossover study was conducted in Australia from May to December 2023, including adults over 18. Participants consumed 300 mg of PEA or a placebo at menstrual pain onset. Pain scores were recorded on the numerical pain rating scale every 30 minutes for up to 4 hours. If pain persisted, a second dose was permitted after 2 hours. PEA resulted in a significant reduction in pain scores at 1 (p = .045), 1.5 (p = .009), 2 (p = .015) and 2.5 (p = .039) hours post-dosage compared to placebo. No difference was seen for the Treatment Satisfaction Questionnaire for Medication, rescue medication used, or adverse events. The study demonstrated that PEA supplementation is a safe and effective option for reducing menstrual pain compared to placebo, with significant pain reduction observed at multiple time points post-dosage.

Endometriosis-Related Pain

A study found that daily supplementation with 800 mg PEA and 80 mg transpolydatin for 90 days significantly reduced endometriosis-related pain.

Chronic Pain Management

Studies indicate that higher doses (such as 600 mg/day) may be more effective than lower doses (such as 300 mg/day), but the specific dosage should be adjusted according to the individual patient’s condition. The recent meta-analysis and systematic review concluded that PEA could be a useful supplement for managing chronic pain conditions with a very good safety profile.

Glaucoma and Neuroinflammation

In Italy, PEA is available as a food supplement (PeaPure) and as a medical dietary food (Normast, PeaVera, and Visimast). These products have been approved in Italy for the nutritional support of glaucoma and neuroinflammatory diseases. Studies have demonstrated the safety and efficacy of PEA when used as a nutritional therapy for glaucoma up to 1.8 grams per day, with excellent tolerability.

The Bioavailability Challenge

Despite its broad therapeutic potential, native PEA presents significant formulation challenges. The compound is highly lipophilic and nearly insoluble in water, with a solubility of just 4 mg/L, making it hard for the body to absorb when taken orally. Studies show that most PEA doesn‘t enter the bloodstream, resulting in low bioavailability and limiting its potential health benefits. The clinical utility of PEA is limited by its poor water solubility, extensive gastrointestinal metabolism, and consequently low oral bioavailability.

These limitations have driven the development of advanced delivery systems, including micronization, ultra-micronization, and liposomal encapsulation. Liposomal delivery systems encapsulate PEA in a lipid bilayer, similar to the body’s cell membranes, and PEA liposomes exhibit improved absorption into the bloodstream, resulting in enhanced bioavailability and efficacy.

Liposomal PEA

Liposomal encapsulation of PEA provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the PEA molecule, forming a protective shell that enhances solubility, stability, and cellular uptake. This delivery system:

• Achieves up to 28 times higher relative bioavailability compared to regular PEA

• Enables instant water dispersibility, forming a stable emulsion

• Enhances gastrointestinal permeation and bioaccessibility by 7-fold compared to micronized PEA

• Provides sustained release with rapid and long-lasting effects

A novel liposomal PEA with enhanced gastrointestinal permeating properties demonstrated significant improvement in PEA‘s permeability and absorption in an ex vivo simulated gastrointestinal environment. In vitro digestion under simulated gastric fluid and simulated intestinal fluid conditions demonstrated that liposomal PEA significantly enhanced the release pattern of PEA into solution, showing an 8-fold enhancement in gastric release and an overall 7-fold increase in bioaccessibility compared to micronized PEA.

Safety and Regulatory

Palmitoylethanolamide is well tolerated and has no serious side effects. Studies have demonstrated the safety and efficacy of PEA when used as a nutritional therapy for glaucoma up to 1.8 grams per day, with excellent tolerability. The oral administration of one gram of PEA per day has also been reported to have no adverse effects. The LD50 of PEA was found to be greater than the limiting dose of 2000 mg/kg body weight in animal studies. The no-effect level for subchronic toxicity studies was the highest dose tested. PEA does not induce gene mutations and genotoxic effects.

Regulatory status varies by region:

• Italy — PEA is available as a food supplement (PeaPure) and as a medical dietary food (Normast, PeaVera, and Visimast).

• Spain — AEMPS and AESAN classify PEA as a “complemento alimenticio” (food supplement) without formal therapeutic indication.

• United States — PEA is sold as a dietary supplement and has achieved Generally Recognized As Safe (GRAS) status.

• European Union — PEA is classified as “Not Novel in Food Supplements.” Any other food uses may be considered as novel.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

109$/KG

99$/KG